The History of baclofen: A Journey from Antiepileptic Aspirant to Spasticity Mainstay and Beyond

Baclofen, a medication recognized for its efficacy as a skeletal muscle relaxant, operates as an agonist of the gamma-aminobutyric acid (GABA) neurotransmitter system within the central nervous system.¹ Its primary mechanism involves the activation of GABA-B receptors, a subclass of GABA receptors that play a crucial role in modulating neuronal excitability.¹ This interaction classifies baclofen as a GABA-ergic agonist, a compound that mimics the effects of GABA in the brain and spinal cord.¹ Currently, baclofen is predominantly used to alleviate muscle spasticity, a condition characterized by increased muscle tone and stiffness, which can arise from various neurological disorders affecting the brain and spinal cord.¹ Beyond its primary indication, research and clinical practice have explored and established off-label applications for baclofen, including its investigation as a treatment for alcohol use disorder, trigeminal neuralgia, and other conditions impacting the nervous system and mental health.¹

Understanding the historical trajectory of a widely utilized medication such as baclofen is of paramount importance for clinicians, researchers, and policymakers alike. Tracing the drug’s origins, its initial therapeutic aspirations, the unexpected turns in its development, and the broadening spectrum of its applications provides critical insights into its fundamental mechanisms of action, the most effective ways to employ it therapeutically, the potential risks associated with its use, and the overarching evolution of medical understanding within the interconnected fields of neurology and pharmacology. Furthermore, a historical perspective can illuminate the multifaceted factors that influence regulatory decisions concerning drug approvals and the subsequent adoption of novel treatments into routine clinical practice. This report aims to provide a comprehensive account of baclofen’s journey, from its inception to its current status, exploring its discovery, the pivotal shift towards spasticity treatment, the pivotal clinical trials that substantiated its uses, the milestones of its regulatory approvals across different geographical regions, the expansion of its therapeutic indications, the advent of intrathecal administration, its global regulatory landscape, the history of its various formulations, significant events that have marked its history, the crucial safety concerns associated with its use, the clinical phenomenon of baclofen withdrawal, and the ongoing controversies and debates surrounding its applications.

The story of baclofen began in 1962 within the laboratories of Ciba-Geigy, a prominent Swiss pharmaceutical company that would later become part of Novartis.¹ The synthesis of this novel compound was the work of Heinrich Keberle, a Swiss chemist whose contribution laid the foundation for a medication that would eventually impact the lives of millions.⁶ Notably, Ciba-Geigy itself was a product of a merger in 1970 between two established Swiss entities, Ciba AG and J.R. Geigy SA.³⁰ However, Keberle’s groundbreaking work occurred prior to this consolidation, while he was affiliated with Ciba-Geigy.⁶ The legacy of Ciba AG stretched back to the mid-19th century, originating in the silk-dyeing industry before strategically diversifying into pharmaceuticals at the turn of the 20th century, ultimately rising to become Switzerland’s largest chemical enterprise by that era.³⁰

Initially, the design of baclofen was driven by the specific therapeutic goal of treating epilepsy, a significant neurological disorder characterized by recurrent seizures.¹ The molecular architecture of baclofen was thoughtfully inspired by gamma-aminobutyric acid (GABA), which serves as the primary inhibitory neurotransmitter within the brain.¹ The fundamental strategy behind this design was to synthesize a more lipophilic analog of GABA. Lipophilicity, or the ability to dissolve in fats, is a crucial property for drugs intended to act on the central nervous system because it enhances their capacity to traverse the blood-brain barrier, a highly selective membrane that restricts the passage of many substances from the bloodstream into the brain tissue.³ The prevailing scientific understanding of epilepsy in the early 1960s suggested that imbalances in neuronal inhibition played a critical role in the pathogenesis of seizures. Therefore, a compound that could effectively augment GABAergic neurotransmission within the brain held promise as a potential antiepileptic agent. The endeavor to modify GABA’s structure to achieve improved pharmacokinetic characteristics, specifically its ability to cross the blood-brain barrier more readily, is a common and logical approach in the field of drug development. However, as history would reveal, this particular structural modification would ultimately lead to a therapeutic application that was quite different from its initial intent, highlighting the intricate and often unpredictable nature of biological systems.

Despite the sound scientific rationale underpinning its design, initial preclinical and early clinical investigations revealed that baclofen was not particularly effective in controlling or preventing seizures in individuals suffering from epilepsy.¹ These findings were met with disappointment, as the pharmaceutical industry and the medical community were actively seeking more effective treatments for this often debilitating neurological condition. However, during these early phases of research, a significant and unexpected observation was made: baclofen demonstrated a notable ability to reduce muscle spasticity in some of the patients who were participating in these trials and who also happened to exhibit this comorbidity.¹ This secondary effect, initially perhaps considered incidental, proved to be a crucial turning point in the history of baclofen. The recognition of this unanticipated therapeutic property prompted researchers and the developing company, Ciba-Geigy, to reconsider the primary focus of baclofen’s development. Instead of pursuing it as an antiepileptic drug, they made the strategic decision to re-evaluate its potential as a treatment for muscle spasticity, a condition characterized by involuntary muscle stiffness and spasms that can significantly impair movement and quality of life. This shift in focus, driven by astute clinical observation, ultimately led to baclofen’s successful establishment as a cornerstone in the management of spasticity arising from various neurological disorders.¹ The reintroduction of baclofen in 1971 specifically as a treatment for spasticity marked this pivotal change in its therapeutic trajectory.¹

Following the realization of baclofen’s potential in treating muscle spasticity, a series of clinical studies were initiated in the late 1960s and early 1970s to rigorously evaluate its efficacy for this specific indication. A significant early study, documented in snippet ⁴⁰, was a double-blind controlled trial conducted in 1966. This research demonstrated that baclofen, then marketed under the brand name Lioresal, was significantly more effective than a placebo in reducing spasticity in patients suffering from lesions affecting the corticospinal tract, a major neural pathway involved in motor control. This early positive outcome provided crucial initial evidence supporting the drug’s new therapeutic direction. Snippet ¹¹ offers a broader perspective, highlighting that oral baclofen has since become a fundamental treatment for spasticity, and reviews the accumulated clinical evidence affirming its effectiveness and safety across a spectrum of underlying causes and degrees of spasticity. However, snippet ⁵ provides a more nuanced view, pointing out that many of the earlier clinical trials investigating oral baclofen for spasticity were conducted several decades ago, often involved relatively small groups of patients, and had shorter durations of follow-up compared to contemporary research standards. This suggests that while the initial evidence was promising, the understanding of baclofen’s long-term efficacy and optimal use has continued to evolve with ongoing research. The early clinical trials primarily focused on evaluating baclofen’s impact on spasticity associated with chronic neurological conditions such as multiple sclerosis and spinal cord injuries.¹ These conditions were, and continue to be, major targets for spasticity-relieving therapies due to the significant functional impairments and reduced quality of life they can cause. The clinical benefits observed in these early studies included effective relief from flexor spasms, a reduction in the frequency and severity of clonus (involuntary, rhythmic muscle contractions), and an overall alleviation of associated pain and muscular rigidity.¹ To provide objective measures of spasticity and the response to treatment, these trials often employed standardized clinical assessment tools, most notably the Ashworth scale and its subsequent modifications.⁵ The consistent use of such scales allowed researchers to quantify the degree of muscle tone and document any changes resulting from baclofen administration, thereby strengthening the evidence for its efficacy.

A significant milestone in the history of baclofen was its regulatory approval by the United States Food and Drug Administration (FDA) in 1977 for the treatment of spasticity.¹ This approval officially recognized baclofen as a safe and effective therapeutic agent for managing muscle spasticity arising from conditions such as multiple sclerosis and spinal cord injuries. The primary brand name under which baclofen was initially marketed in the United States and many other parts of the world was Lioresal.¹ This brand name became widely associated with baclofen and remains recognized in clinical practice today. Over the subsequent years, particularly following the expiration of the original patents protecting baclofen, the medication has become widely available as a generic drug.⁶ This widespread availability of generic formulations has significantly increased the affordability and accessibility of baclofen for patients who require it, making it a more readily available treatment option in healthcare systems globally.

While baclofen’s initial FDA approval in 1977 was for the treatment of spasticity, its clinical applications have expanded considerably over the ensuing decades, driven by ongoing scientific research and astute clinical observations.¹ One of the most notable areas of expanded use has been its investigation and off-label application for the treatment of alcohol use disorder (AUD).¹ As highlighted in snippet ⁶, clinical trials have explored the potential of high-dose baclofen in treating AUD, with one notable initiative being a clinical trial in Amsterdam inspired by the work of Olivier Ameisen. Furthermore, snippet ³ indicates the existence of randomized controlled trials specifically evaluating baclofen’s efficacy in patients with AUD. While early findings, as suggested in snippet ⁸³, initially sparked optimism about baclofen as a potential “wonder drug” for AUD, subsequent research, including meta-analyses, has yielded mixed results, leading to ongoing debate within the medical community. The personal account of physician Olivier Ameisen, detailed in snippet ⁸⁴, who successfully used baclofen to overcome his own severe alcoholism and documented his experience in a 2008 book, significantly raised public and medical awareness of this potential off-label application. This eventually culminated in a significant regulatory development in France, which, as noted in snippets ⁸⁵ and ⁸⁵, became the first country to officially approve baclofen for the treatment of AUD in October 2018.⁸⁶ Beyond its investigation for AUD, baclofen has also been explored and used off-label for a range of other conditions. Snippet ³ mentions its use as an analgesic for certain types of chronic pain, specifically cranial nerve-related neuropathic pains such as trigeminal neuralgia. Snippet ⁹ further lists trigeminal neuralgia, gastroesophageal reflux disease (GERD), and intractable hiccups as recognized off-label applications of baclofen. Additionally, as mentioned in snippet ⁶, there has been interest in its potential role in managing the often distressing symptoms associated with opioid withdrawal. These diverse applications highlight the complex pharmacological profile of baclofen and its ability to interact with various neurochemical pathways beyond those primarily responsible for regulating muscle tone.

A significant advancement in the therapeutic use of baclofen for managing severe spasticity was the development and introduction of intrathecal baclofen (ITB) therapy.¹ As noted in snippet ⁶, intrathecal baclofen was first introduced in 1984 as a treatment specifically for severe spasticity originating from the spinal cord. This method of administration involves the surgical implantation of a pump that delivers baclofen directly into the intrathecal space, which is the area surrounding the spinal cord containing cerebrospinal fluid. A key discovery, highlighted in snippet ⁷⁵, was made in the early 1980s, revealing that baclofen was significantly more effective in reducing spasticity when administered directly to the central nervous system via this intrathecal route. Snippet ⁹⁹ further details the pivotal research milestones in the development of ITB therapy, including Dr. Tony Yaksh’s investigations into the analgesic effects of intraspinal baclofen in primates in 1981 and Dr. Richard Penn’s groundbreaking studies on the intraspinal administration of baclofen for hypertonicity in rabbits, which he subsequently expanded to human subjects starting in 1984. The primary advantage of ITB therapy over oral baclofen is its ability to deliver the medication directly to the spinal cord, the primary site of action for its muscle relaxant effects.⁷⁵ This targeted delivery allows for the use of much lower doses of baclofen compared to oral administration, as the drug bypasses the blood-brain barrier and reaches higher concentrations in the cerebrospinal fluid surrounding the spinal cord.⁵ Consequently, patients often experience a substantial reduction in the systemic side effects that are commonly associated with oral baclofen, such as drowsiness and fatigue.⁵ The regulatory approval timeline for intrathecal baclofen in the United States culminated in its initial FDA approval in 1992. Notably, this approval was granted under the orphan drug designation.⁶¹ Orphan drug status is often given to medications developed to treat rare diseases or conditions, which can provide incentives for pharmaceutical companies to invest in their development. Snippet ⁹⁹ further specifies that in 1992, baclofen was also approved for administration through implantable infusion pumps, solidifying ITB therapy as a viable treatment option for severe spasticity.

The regulatory landscape for baclofen varies across different regions of the world. While its primary indication for treating spasticity is widely recognized and approved in numerous countries, the specific timelines and additional approved uses can differ. A notable divergence is seen in the approval of baclofen for alcohol use disorder (AUD). As mentioned previously, France made a significant regulatory decision in October 2018, becoming the first country to officially approve baclofen for this indication.³ This decision followed a period of extensive off-label use and considerable debate within the French medical and scientific communities regarding its efficacy and safety in treating AUD. In contrast, while baclofen is available in Canada and widely used for the treatment of spasticity, the provided research snippets do not specify the exact date of its initial approval in Canada for this purpose.¹ However, these snippets do confirm that baclofen is currently marketed and available in Canada through various pharmaceutical companies under different brand names, primarily for its established role in managing muscle spasticity. Further research into the regulatory history of baclofen in other European countries, Australia, and Asia would be necessary to gain a more comprehensive understanding of its global regulatory landscape.

Over the course of its history, baclofen has been formulated and made available in various pharmaceutical forms to accommodate different patient needs and routes of administration.¹ The most common formulation is oral tablets, which are available in several dosage strengths, typically including 5mg, 10mg, and 20mg.¹ These varying strengths allow physicians to titrate the dosage gradually to achieve the optimal therapeutic effect while minimizing potential side effects. In addition to tablets, oral solutions and suspensions have been developed to provide alternative administration routes, particularly for patients who experience difficulty swallowing solid dosage forms or who require medication through feeding tubes. Examples of these include Lyvispah oral granules, available in 5mg, 10mg, and 20mg packets ¹, and Fleqsuvy oral suspension.¹ For intrathecal baclofen therapy, specialized intrathecal solutions are available in various concentrations, including 0.05mg/mL, 0.5mg/mL, 1mg/mL, and 2mg/mL.¹ These different concentrations allow for precise and controlled delivery of the medication via implantable pumps.

The history of baclofen is punctuated by several notable events and research milestones that have significantly influenced its understanding and clinical application. The initial discovery of its effectiveness in reducing spasticity in the late 1960s and early 1970s, following its initial failure as an antiepileptic drug, marked a crucial turning point.¹ The FDA’s decision to approve baclofen for the treatment of spasticity in 1977 was another pivotal moment, officially establishing its therapeutic role for this condition.¹ The introduction of intrathecal baclofen therapy in 1984 represented a major advancement in the management of severe spasticity, offering a more targeted and often more effective treatment option.¹ The publication of French-American cardiologist Olivier Ameisen’s memoir in 2008, detailing his successful self-treatment for severe alcoholism using high-dose baclofen, significantly increased interest and spurred research into the potential of baclofen for AUD.¹ France’s decision in 2018 to approve baclofen for the treatment of alcohol use disorders marked a unique regulatory milestone.³ More recently, the FDA approvals of new oral formulations like Lyvispah (oral granules) in 2021 and Fleqsuvy (oral suspension) in 2022 have provided enhanced convenience and administration options for patients with spasticity.⁴¹

When used within the recommended dosage range for its approved indications, baclofen generally exhibits a well-established safety profile. However, it is important for both patients and healthcare providers to be aware of potential side effects. Common side effects include drowsiness, dizziness, fatigue, and muscle weakness.¹ More serious adverse effects, although less common, can occur. Notably, abrupt discontinuation of baclofen, especially after prolonged use or at high doses, carries a risk of precipitating seizures and rhabdomyolysis, a potentially dangerous condition involving muscle breakdown.⁶ Therefore, careful management is essential when discontinuing treatment, typically involving a gradual reduction in dosage under the guidance of a healthcare professional. There are also specific contraindications for baclofen use. For instance, it is generally avoided in patients with significant chronic kidney disease or end-stage renal disease because the impaired ability to eliminate the drug can lead to excessive and potentially toxic levels in the body, even at relatively low doses.⁶ Furthermore, baclofen can interact with other medications, most notably with other central nervous system depressants such as alcohol and benzodiazepines.¹ Concurrent use can potentiate the effects of these substances, leading to increased sedation, respiratory depression, and an elevated risk of other adverse events. Interactions with pain medications, including ibuprofen and opioids, have also been reported, potentially increasing the risk of side effects.²²

The baclofen withdrawal syndrome is a clinically significant concern that can arise following the abrupt cessation or a substantial reduction in the dose of baclofen, particularly after prolonged use or with intrathecal administration.¹ The symptoms associated with this withdrawal syndrome can vary in severity and may include a rebound increase in muscle spasticity, agitation, anxiety, the occurrence of visual and auditory hallucinations, seizures, confusion, and hyperthermia.¹ In severe cases, baclofen withdrawal can lead to potentially life-threatening complications such as rhabdomyolysis and multi-organ failure. Therefore, it is critically important to discontinue baclofen therapy only under the close supervision of a healthcare professional, and in most circumstances, a gradual tapering of the dose is strongly recommended to minimize the risk and severity of these withdrawal symptoms.²² The baclofen withdrawal syndrome can be particularly pronounced and potentially life-threatening in patients who are receiving the medication via intrathecal administration.⁶ In these cases, any interruption of the baclofen infusion, whether due to pump malfunction, catheter issues, or sudden cessation of therapy, necessitates immediate medical intervention to manage the potentially severe withdrawal symptoms.

The use of baclofen, particularly in applications beyond its primary approved indication for spasticity, has been a subject of various controversies and ongoing debates within the medical and scientific communities.⁴ A significant area of contention revolves around the effectiveness and safety of baclofen in the treatment of alcohol use disorder (AUD).¹ While some clinical trials and anecdotal reports have suggested potential benefits, especially with the use of higher doses, other studies and meta-analyses have yielded conflicting and often inconclusive results. This inconsistency in the evidence base has led to ongoing uncertainty and debate among healthcare professionals regarding the widespread adoption of baclofen as a standard treatment for AUD. Furthermore, there is considerable variability in how individual patients respond to baclofen, particularly in the context of AUD treatment.¹² The optimal effective dose can differ significantly from one patient to another, and a universally established dosing regimen has yet to be defined. This variability presents challenges for clinicians in determining the most appropriate and effective treatment strategy for each individual struggling with alcohol dependence. Another area of concern involves the safety of baclofen, particularly its potential for misuse, abuse, and dependence, especially when it is used off-label at doses exceeding those typically prescribed for managing spasticity.⁶ There have been reports of individuals experiencing euphoria and engaging in drug-seeking behavior related to baclofen use, raising concerns about its potential for recreational abuse, particularly in individuals with a history of substance use disorders. These safety considerations underscore the importance of cautious prescribing practices, thorough patient evaluation, and careful monitoring when baclofen is considered for off-label applications.

In conclusion, the history of baclofen is a compelling narrative of scientific discovery, unexpected therapeutic applications, and ongoing exploration. Originating from an endeavor to develop a novel antiepileptic drug, baclofen unexpectedly revealed its efficacy in treating muscle spasticity, becoming a cornerstone medication for managing this often debilitating condition. The advent of intrathecal baclofen therapy marked a significant advancement, offering a more targeted and effective treatment for severe cases unresponsive to oral medications. While its primary role in spasticity management remains firmly established, the journey of baclofen has continued with the exploration of its potential in treating other conditions, most notably alcohol use disorder. This off-label application has generated considerable research interest and regulatory action in some regions, yet it remains a subject of ongoing debate within the medical community. As with any pharmacologically active agent, the use of baclofen is associated with important safety considerations, including the potential for side effects, contraindications in specific patient populations, and the risk of a significant withdrawal syndrome upon abrupt cessation. The controversies surrounding its off-label uses and the potential for misuse underscore the need for continued research to optimize its therapeutic applications and ensure its safe and effective use in diverse clinical settings.

Works cited

1. baclofen: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed May 6, 2025, https://go.drugbank.com/drugs/DB00181
2. baclofen | C10H12ClNO2 | CID 2284 – PubChem, accessed May 6, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/baclofen
3. Classics in Chemical Neuroscience: baclofen | Request PDF – ResearchGate, accessed May 6, 2025, https://www.researchgate.net/publication/341557283_Classics_in_Chemical_Neuroscience_baclofen
4. Classics in Chemical Neuroscience: baclofen – ACS Publications, accessed May 6, 2025, https://pubs.acs.org/doi/abs/10.1021/acschemneuro.0c00254
5. Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen – HTML, accessed May 6, 2025, https://www.medicaljournals.se/jrm/content/html/10.2340/16501977-2211
6. baclofen – Wikipedia, accessed May 6, 2025, https://en.wikipedia.org/wiki/baclofen
7. Is baclofen Addictive? Risks, Withdrawal, and Safe Use – Agape Detox Center, accessed May 6, 2025, https://agapedetoxcenter.com/is-baclofen-addictive/
8. Intrathecal baclofen Therapy for Spasticity – Northwest Regional Spinal Cord Injury System, accessed May 6, 2025, https://sci.washington.edu/info/forums/reports/intrathecal_baclofen.asp
9. baclofen – StatPearls – NCBI Bookshelf, accessed May 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK526037/
10. What is baclofen and how does it work in alcohol addiction?, accessed May 6, 2025, https://baclofentreatment.com/background/science/what-is-baclofen-and-how-does-it-work-in-alcohol-addiction/
11. Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen – ResearchGate, accessed May 6, 2025, https://www.researchgate.net/publication/314024984_Efficacy_and_safety_of_oral_baclofen_in_the_management_of_spasticity_A_rationale_for_intrathecal_baclofen
12. A Review of the Potential Mechanisms of Action of baclofen in Alcohol Use Disorder, accessed May 6, 2025, https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2018.00506/full
13. What to know about baclofen and alcohol – Medical News Today, accessed May 6, 2025, https://www.medicalnewstoday.com/articles/baclofen-and-alcohol
14. The Use of baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective – PubMed Central, accessed May 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6328471/
15. baclofen | EBSCO Research Starters, accessed May 6, 2025, https://www.ebsco.com/research-starters/health-and-medicine/baclofen
16. The Use of baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective – Frontiers, accessed May 6, 2025, https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2018.00708/full
17. Is baclofen Addictive? What You Should Know – Discovery Institute, accessed May 6, 2025, https://www.discoverynj.org/is-baclofen-addictive-what-is-it-used-for/
18. baclofen Toxicity – StatPearls – NCBI Bookshelf, accessed May 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK580550/
19. baclofen therapeutics, toxicity, and withdrawal: A narrative review – PMC – PubMed Central, accessed May 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8182184/
20. baclofen (baclofen Tablets): Side Effects, Uses, Dosage, Interactions, Warnings – RxList, accessed May 6, 2025, https://www.rxlist.com/baclofen-drug.htm
21. baclofen (Lioresal, Fleqsuvy, and others): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing – WebMD, accessed May 6, 2025, https://www.webmd.com/drugs/2/drug-8615/baclofen-lioresal-fleqsuvy-and-others/details
22. baclofen Tablets: Uses, Interactions & Side Effects – Cleveland Clinic, accessed May 6, 2025, https://my.clevelandclinic.org/health/drugs/19760-baclofen-tablets
23. baclofen: Uses in Addiction Treatment & Side Effects, accessed May 6, 2025, https://americanaddictioncenters.org/addiction-medications/baclofen
24. baclofen: uses, dosing, warnings, adverse events, interactions – MedCentral, accessed May 6, 2025, https://www.medcentral.com/drugs/monograph/8615-382530/baclofen-oral
25. baclofen (oral route) – Mayo Clinic, accessed May 6, 2025, https://www.mayoclinic.org/drugs-supplements/baclofen-oral-route/description/drg-20067995
26. baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders – Frontiers, accessed May 6, 2025, https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2018.00464/full
27. An Unusual Case of baclofen Abuse – PMC – PubMed Central, accessed May 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5052965/
28. en.wikipedia.org, accessed May 6, 2025, https://en.wikipedia.org/wiki/baclofen#:~:text=insoluble%20in%20chloroform.-,History,chemist%20Heinrich%20Keberle%20in%201962.
29. baclofen for spinal muscular atrophy – SMA News Today, accessed May 6, 2025, https://smanewstoday.com/baclofen/
30. www.britannica.com, accessed May 6, 2025, https://www.britannica.com/money/Ciba-Geigy-AG#:~:text=Ciba%2DGeigy%20AG%2C%20Former%20Swiss,largest%20chemical%20company%20in%20Switzerland.
31. Ciba-Geigy AG | Merger, Agrochemicals, Pharmaceuticals, accessed May 6, 2025, https://www.britannica.com/money/Ciba-Geigy-AG
32. History and structure of Ciba-Geigy – ResearchGate, accessed May 6, 2025, https://www.researchgate.net/profile/William_Vorley/publication/272176010_Reconciling_shareholders_stakeholders_and_managers_Experiencing_the_Ciba-Geigy_Vision_for_Sustainable_Development/links/54de0f050cf22a26721e2d5a
33. Ciba-Geigy AG – Heddels, accessed May 6, 2025, https://www.heddels.com/dictionary/ciba-geigy-ag/
34. Company History | Novartis United Kingdom, accessed May 6, 2025, https://www.novartis.com/uk-en/about/who-we-are/company-history
35. Ciba-geigy Ltd | Encyclopedia.com, accessed May 6, 2025, https://www.encyclopedia.com/social-sciences-and-law/economics-business-and-labor/businesses-and-occupations/ciba-geigy-ltd
36. The Basel marriage: History of the Ciba-Geigy merger: Erni, Paul – Amazon.com, accessed May 6, 2025, https://www.amazon.com/Basel-marriage-History-Ciba-Geigy-merger/dp/B0007AOUMC
37. Novartis – Wikipedia, accessed May 6, 2025, https://en.wikipedia.org/wiki/Novartis
38. Intrathecal baclofen for dystonia treatment during pregnancy: A case report | Neurología (English Edition) – Elsevier, accessed May 6, 2025, https://www.elsevier.es/en-revista-neurologia-english-edition–495-articulo-intrathecal-baclofen-for-dystonia-treatment-S2173580816000134
39. Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial | Brain Communications | Oxford Academic, accessed May 6, 2025, https://academic.oup.com/braincomms/article/4/6/fcac300/6841350
40. baclofen in the treatment of spasticity – PubMed, accessed May 6, 2025, https://pubmed.ncbi.nlm.nih.gov/4938243/
41. Clinical Review {Susanne R. Goldstein} {NDA 215422} {baclofen oral granules} CDER Clinical Review Template 1 Version date – FDA, accessed May 6, 2025, https://www.fda.gov/media/155330/download
42. baclofen (Lioresal) – MS Trust, accessed May 6, 2025, https://mstrust.org.uk/a-z/baclofen-lioresal-lyflex
43. US FDA Approves Oral Formulations of baclofen for MS-Related Muscle Spasticity: Lyvispah™ and Fleqsuvy™ Now Available, accessed May 6, 2025, https://www.nationalmssociety.org/news-and-magazine/news/fda-approves-baclofen-oral-formulations
44. baclofen Oral Suspension Approved for Treatment of Spasticity in Multiple Sclerosis, accessed May 6, 2025, https://www.neurologylive.com/view/baclofen-oral-suspension-approved-treatment-spasticity-multiple-sclerosis
45. baclofen: What Foods or Medications to Avoid – Healthline, accessed May 6, 2025, https://www.healthline.com/health/drugs/baclofen-what-to-avoid
46. 8 baclofen Side Effects to Know About Before Taking It – GoodRx, accessed May 6, 2025, https://www.goodrx.com/baclofen/baclofen-side-effects
47. www.mayoclinic.org, accessed May 6, 2025, https://www.mayoclinic.org/drugs-supplements/baclofen-oral-route/description/drg-20067995#:~:text=This%20medicine%20may%20cause%20dizziness,and%20able%20to%20see%20well.
48. baclofen: MedlinePlus Drug Information, accessed May 6, 2025, https://medlineplus.gov/druginfo/meds/a682530.html
49. baclofen Uses, Dosage & Side Effects – Drugs.com, accessed May 6, 2025, https://www.drugs.com/baclofen.html
50. Who can and cannot take baclofen – NHS, accessed May 6, 2025, https://www.nhs.uk/medicines/baclofen/who-can-and-cannot-take-baclofen/
51. baclofen | Poisoning & Drug Overdose, 7e | AccessMedicine | McGraw Hill Medical, accessed May 6, 2025, https://accessmedicine.mhmedical.com/content.aspx?sectionid=248383628
52. Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders, accessed May 6, 2025, https://investors.amneal.com/news/press-releases/press-release-details/2022/Amneal-Launches-LYVISPAH-baclofen-for-Spasticity-Related-to-Multiple-Sclerosis-and-Other-Spinal-Cord-Disorders/default.aspx
53. Office of Clinical Pharmacology (Fleqsuvy) – FDA, accessed May 6, 2025, https://www.fda.gov/media/158272/download
54. Fleqsuvy (baclofen) FDA Approval History – Drugs.com, accessed May 6, 2025, https://www.drugs.com/history/fleqsuvy.html
55. About baclofen – NHS, accessed May 6, 2025, https://www.nhs.uk/medicines/baclofen/about-baclofen/
56. Lioresal, Gablofen (baclofen) dosing, indications, interactions, adverse effects, and more., accessed May 6, 2025, https://reference.medscape.com/drug/lioresal-baclofen-343335
57. Lioresal Dosage Guide – Drugs.com, accessed May 6, 2025, https://www.drugs.com/dosage/lioresal.html
58. baclofen Dosage Guide: Adjustments and Tips – GoodRx, accessed May 6, 2025, https://www.goodrx.com/baclofen/dosage
59. An Introduction to Trialing Intrathecal baclofen in Patients with Hemiparetic Spasticity: A Description of 3 Cases – :::::Pain Physician:::::, accessed May 6, 2025, https://www.painphysicianjournal.com/current/pdf?article=MTUxMQ==&journal=63
60. Intrathecal baclofen for Spastic Hypertonia From Stroke, accessed May 6, 2025, https://www.ahajournals.org/doi/10.1161/hs0901.095682
61. LIORESAL ®INTRATHECAL – accessdata.fda.gov, accessed May 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020075s021lbl.pdf
62. Intrathecal baclofen Pump for Spasticity: An Evidence-Based Analysis – PMC, accessed May 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3382401/
63. Case report: Intrathecal baclofen therapy improved gait pattern in a stroke patient with spastic dystonia – Frontiers, accessed May 6, 2025, https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1330811/full
64. Effect of Intrathecal baclofen on Pain and Quality of Life in Poststroke Spasticity | Stroke, accessed May 6, 2025, https://www.ahajournals.org/doi/10.1161/STROKEAHA.118.022255
65. Clinical Review(s) – accessdata.fda.gov, accessed May 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/208193Orig1s000MedR.pdf
66. Product Quality Review(s) – accessdata.fda.gov, accessed May 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/208193Orig1s000ChemR.pdf
67. Generic Lioresal Availability – Drugs.com, accessed May 6, 2025, https://www.drugs.com/availability/generic-lioresal.html
68. Lioresal® Intrathecal – Amneal Biosciences, accessed May 6, 2025, https://amnealbiosciences.com/lioresal/
69. Lioresal – Novartis, accessed May 6, 2025, https://www.novartis.com/sg-en/sites/novartis_sg/files/Lioresal-Nov2021.SIN-App240122.pdf
70. EX-99.1 – SEC.gov, accessed May 6, 2025, https://www.sec.gov/Archives/edgar/data/1723128/000119312522002140/d283868dex991.htm
71. Amneal Acquires Saol Therapeutics’ baclofen Franchise, accessed May 6, 2025, https://investors.amneal.com/news/press-releases/press-release-details/2022/Amneal-Acquires-Saol-Therapeutics-baclofen-Franchise/default.aspx
72. About Lioresal® Intrathecal – HCP, accessed May 6, 2025, https://lioresal.com/hcp/about-lioresal-intrathecal/
73. PRODUCT MONOGRAPH – Novartis, accessed May 6, 2025, https://www.novartis.com/ca-en/sites/novartis_ca/files/lioresalIT_scrip_e.pdf
74. baclofen Injection: Package Insert / Prescribing Information – Drugs.com, accessed May 6, 2025, https://www.drugs.com/pro/baclofen-injection.html
75. FDA Approves Movement Disorder Drug from CNS Therapeutics: Gablofen® (baclofen Injection) for the Treatment of Severe Spas | Fierce Pharma, accessed May 6, 2025, https://www.fiercepharma.com/pharma/fda-approves-movement-disorder-drug-from-cns-therapeutics-gablofen%C2%AE-baclofen-injection-for
76. What to Expect – Lioresal Intrathecal (baclofen injection), accessed May 6, 2025, https://lioresal.com/screening-trial/what-to-expect/
77. LIORESAL® INTRATHECAL – accessdata.fda.gov, accessed May 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020075s037lbl.pdf
78. Overdose and Withdrawal Warning Signs ITB Therapy for Severe Spasticity – Medtronic, accessed May 6, 2025, https://www.medtronic.com/en-us/l/patients/treatments-therapies/drug-pump-severe-spasticity/living-with-itb-therapy/overdose-withdrawal-warning-signs.html
79. baclofen Withdrawal & Detox: Symptoms, Timeline and Treatment – The Recovery Village, accessed May 6, 2025, https://www.therecoveryvillage.com/baclofen-addiction/withdrawal-detox/
80. baclofen Withdrawal: Symptoms, Timeline, & Treatment, accessed May 6, 2025, https://www.banyantreatmentcenter.com/blog/baclofen-withdrawal-symptoms-timeline-treatment/
81. Dosing – Lioresal Intrathecal (baclofen injection), accessed May 6, 2025, https://lioresal.com/lioresal-intrathecal/dosing/
82. Full Prescribing Information | Lioresal Intrathecal | ITB Therapy – Medtronic, accessed May 6, 2025, https://www.medtronic.com/en-us/l/patients/treatments-therapies/drug-pump-severe-spasticity-full-prescribing-information.html
83. Scientists discovered a wonder drug for alcohol use disorder ineffective – Tech Explorist, accessed May 6, 2025, https://www.techexplorist.com/scientists-discovered-wonder-drug-alcohol-use-disorder-ineffective/12103/
84. The Olivier Ameisen Story – baclofen Treatment for Alcoholism, accessed May 6, 2025, https://baclofentreatment.com/background/stories/the-olivier-ameisen-story/
85. Approval of baclofen for Alcohol Use Disorders in France: A Perspective From the United States – Oxford Academic, accessed May 6, 2025, https://academic.oup.com/alcalc/article-abstract/55/1/48/5639732
86. baclofen approval in france: A balance between two conceptions of medicine | European Psychiatry – Cambridge University Press, accessed May 6, 2025, https://www.cambridge.org/core/journals/european-psychiatry/article/baclofen-approval-in-france-a-balance-between-two-conceptions-of-medicine/2490CD2853549764CA884F2CBE5B9780
87. baclofen in the treatment of alcohol use disorder: tailored doses matter – Oxford Academic, accessed May 6, 2025, https://academic.oup.com/alcalc/article/59/2/agad090/7585887
88. baclofen approval in France: A balance between two conceptions of medicine, accessed May 6, 2025, https://www.researchgate.net/publication/355488274_baclofen_approval_in_France_A_balance_between_two_conceptions_of_medicine
89. EMEA-001549-PIP02-14 – paediatric investigation plan – EMA – European Union, accessed May 6, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001549-pip02-14
90. baclofen for Alcohol Use Disorder: Cochrane Review Insights – RTI International, accessed May 6, 2025, https://www.rti.org/rti-press-publication/baclofen-alcohol-use-disorder-cochrane-review-summary-commentary
91. baclofen in the Treatment of Alcohol Use Disorder | Frontiers Research Topic, accessed May 6, 2025, https://www.frontiersin.org/research-topics/7165/baclofen-in-the-treatment-of-alcohol-use-disorder/magazine
92. Efficacy and Safety of baclofen for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial, accessed May 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2965272/
93. Dose–Response Effect of baclofen in Reducing Daily Alcohol Intake in Alcohol Dependence: Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial – Oxford Academic, accessed May 6, 2025, https://academic.oup.com/alcalc/article/46/3/312/239866
94. ISRCTN17435333: Trial exploring the benefits of different doses of baclofen for patients with alcohol addiction – ISRCTN Registry, accessed May 6, 2025, https://www.isrctn.com/ISRCTN17435333
95. Clinical Trials of baclofen for Alcoholism: 2018 Update, accessed May 6, 2025, https://baclofentreatment.com/background/science/clinical-trials-of-baclofen-for-alcoholism-2018-update/
96. www.tga.gov.au, accessed May 6, 2025, https://www.tga.gov.au/news/safety-updates/use-caution-when-prescribing-baclofen-label#:~:text=Cases%20of%20misuse%2C%20abuse%20and,seeking%20behaviour%2C%20development%20of%20tolerance.
97. If baclofen is so great, why isn’t everyone using it already?, accessed May 6, 2025, https://baclofentreatment.com/questions-controversies/if-baclofen-is-so-great-why-isnt-everyone-using-it-already/
98. Use caution when prescribing baclofen off label | Therapeutic Goods Administration (TGA), accessed May 6, 2025, https://www.tga.gov.au/news/safety-updates/use-caution-when-prescribing-baclofen-label
99. baclofen: A Historical Journey and Modern Applications in Spasticity Management – Hartley Medical, accessed May 6, 2025, https://www.hartleymedical.com/blog-posts/intrathecal-baclofen-a-review-2012
100. New Way to Administer Spasticity-Preventing Drug Reaches Clinical Trials | RIO, accessed May 6, 2025, https://research.umn.edu/news/new-way-administer-spasm-preventing-drug-reaches-clinical-trials
101. Search for baclofen – Clinical Trials register, accessed May 6, 2025, https://www.clinicaltrialsregister.eu/ctr-search/search?query=baclofen&page=3
102. Long-term use of Continuously Delivered baclofen Medication for Excessive Abnormal Muscle Tone – Brain Injury Association of America, accessed May 6, 2025, https://biausa.org/professionals/research/tbi-model-systems/long-term-use-of-continuously-delivered-baclofen-medication-for-excessive-abnormal-muscle-tone
103. Benefit of enteral baclofen in the management of spasticity in cerebral palsy – PMC, accessed May 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10116133/
104. baclofen, Botox, and More: 5 Cerebral Palsy Medications for Spasticity – GoodRx, accessed May 6, 2025, https://www.goodrx.com/conditions/cerebral-palsy/cerebral-palsy-medication-spasticity
105. Intrathecal baclofen Therapy for Adults with Spinal Spasticity: Therapeutic Efficacy and Effect on Hospital Admissions, accessed May 6, 2025, https://www.cambridge.org/core/services/aop-cambridge-core/content/view/976DF9EDBC8E0473AA4D32A681BA8883/S0317167100040452a.pdf/intrathecal-baclofen-therapy-for-adults-with-spinal-spasticity-therapeutic-efficacy-and-effect-on-hospital-admissions.pdf
106. baclofen Pump: What It Is, Side Effects & Complications – Cleveland Clinic, accessed May 6, 2025, https://my.clevelandclinic.org/health/treatments/8997-intrathecal-baclofen-pump
107. baclofen Pump Therapy for the Treatment of Spasticity – Michigan Medicine, accessed May 6, 2025, https://www.med.umich.edu/1libr/PMR/baclofenPumpTherapy.pdf
108. Efficacy and Immunological Impact of Intrathecal baclofen Pumps in Managing Spasticity in Multiple Sclerosis in Adult Patients: A Systematic Review – MDPI, accessed May 6, 2025, https://www.mdpi.com/2813-3064/3/1/2
109. Intrathecal baclofen for Reducing Spasticity – SCIRE Professional, accessed May 6, 2025, https://scireproject.com/evidence/spasticity/pharmacological-treatment-for-spasticity/intrathecal-baclofen-for-reducing-spasticity/
110. Examining the effectiveness of intrathecal baclofen on spasticity in individuals with chronic spinal cord injury: A systematic review – PMC, accessed May 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4066544/
111. Reversible Electrocardiogram Changes and Cardiomyopathy Secondary to baclofen Withdrawal Syndrome – Radcliffe Cardiology, accessed May 6, 2025, https://www.radcliffecardiology.com/articles/reversible-electrocardiogram-changes-and-cardiomyopathy-secondary-baclofen-withdrawal?language_content_entity=en
112. baclofen Withdrawal – REBEL EM – Emergency Medicine Blog, accessed May 6, 2025, https://rebelem.com/baclofen-withdrawal/
113. baclofen: therapy, intoxication, & withdrawal – EMCrit Project, accessed May 6, 2025, https://emcrit.org/ibcc/baclofen/
114. Long-term Dosing – HCP – Lioresal Intrathecal (baclofen injection), accessed May 6, 2025, https://lioresal.com/hcp/dosing-and-administration/long-term-dosing/
115. Details for: baclofen – Drug and Health Products Portal, accessed May 6, 2025, https://dhpp.hpfb-dgpsa.ca/dhpp/resource/103324
116. PRODUCT MONOGRAPH PrMYLAN-baclofen, accessed May 6, 2025, https://pdf.hres.ca/dpd_pm/00041627.PDF
117. Details for: APO-baclofen – Drug and Health Product Register, accessed May 6, 2025, https://hpr-rps.hres.ca/details.php?drugproductid=560&query=
118. Listing of Drugs Currently Regulated as New Drugs (The New Drugs List) – Canada.ca, accessed May 6, 2025, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/listing-drugs-currently-regulated-new-drugs.html
119. Population Pharmacokinetics of Oral baclofen in Pediatric Patients with Cerebral Palsy, accessed May 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3992203/
120. Lyvispah (baclofen) FDA Approval History – Drugs.com, accessed May 6, 2025, https://www.drugs.com/history/lyvispah.html
121. baclofen Tablets 10mg – Summary of Product Characteristics (SmPC) – (emc) | 2594, accessed May 6, 2025, https://www.medicines.org.uk/emc/product/2594/smpc
122. Side effects of baclofen – NHS, accessed May 6, 2025, https://www.nhs.uk/medicines/baclofen/side-effects-of-baclofen/
123. pmc.ncbi.nlm.nih.gov, accessed May 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5167087/#:~:text=Withdrawal%20from%20baclofen%20can%20have,%2C%20hyperthermia%2C%20and%20increased%20spasticity.
124. baclofen Withdrawal Symptoms: Signs to Watch For – Ocean Recovery, accessed May 6, 2025, https://www.oceanrecovery.com/addiction-blog/baclofen-withdrawal-symptoms/